The hormone erythropoietin (Epo) controls red blood cell production and synthetic forms of Epo treat multiple disorders. New Vanderbilt research details how Epo works.

Vanderbilt researchers have found that non-coding regions of the genome appear to contribute to the risk of autoimmune diseases and may represent attractive therapeutic targets.

Signaling through a complex of proteins called mTORC2 plays a role in breast cancer migration, invasion and metastasis, Vanderbilt researchers reported.

Bile acids produced by a western diet alter the composition of the gut microbiota and promote intestinal carcinogenesis.

The identification of a genetic culprit for hypoplastic left heart syndrome could lead to new treatments for the condition.

A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.

Vanderbilt investigators have conducted a first-of-its-kind genome-wide association study of lung cancer survival in African-Americans.